文献速递免疫规划传染病防控与疫情报告

13价肺炎球菌结合疫苗引入冈比亚农村10年后对肺炎球菌携带的影响:一项基于人群的横断面研究

Effect of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in rural Gambia 10 years after its introduction: A population-based cross-sectional study.
PubMed 文献 · Vaccine · 2025-04-28

2022年1月至11月在冈比亚中河区和上河区开展基于人群的横断面肺炎球菌携带调查,纳入4087名各年龄段家庭成员。肺炎球菌总携带率为32.1%(95%CI:29.34%-35.03%),PCV13疫苗型携带率为6.4%(95%CI:5.48%-7.47%);5-9岁儿童疫苗型携带率最高(13.6%,95%CI:10.34%-17.56%)。PCV13引入10年后疫苗型携带仍持续存在,尤其在婴儿期免疫直接保护已减弱的年龄组。

要点

  • 肺炎球菌总携带率为32.1%,PCV13疫苗型携带率为6.4%。
  • 5-9岁儿童疫苗型携带率最高,为13.6%。
  • 在完成PCV接种的10岁以下儿童中,5-9岁儿童疫苗型携带的比值比0-11月龄婴儿高1.60倍(AOR=1.60,95%CI:1.06-2.41)。

核心结论

  • PCV13引入冈比亚10年后,疫苗型肺炎球菌携带仍持续存在,尤其在婴儿期免疫直接保护已减弱的年龄组;作者认为加强针或补种接种可能有助于控制疫苗型循环。

研究设计与样本

  • 2022年1月至11月在冈比亚中河区和上河区开展基于人群的横断面肺炎球菌携带调查,随机选取各年龄段家庭成员,采集鼻咽拭子,采用标准方法分离和血清分型肺炎球菌,共纳入4087名参与者。

主要发现

  • 肺炎球菌总携带率为32.1%(95%CI:29.34%-35.03%)。
  • PCV13疫苗型携带率为6.4%(95%CI:5.48%-7.47%)。
  • 5-9岁儿童疫苗型携带率最高,为13.6%(95%CI:10.34%-17.56%)。
  • 在完成PCV接种的10岁以下儿童中,5-9岁儿童疫苗型携带的比值比0-11月龄婴儿高1.60倍(AOR=1.60,95%CI:1.06-2.41)。
  • 在完成PCV接种与未接种的10岁以下儿童中,疫苗型携带率相似;19F、3和6A为最常见的疫苗型血清型,19F在<5岁儿童中最常见,3在5-14岁儿童中最常见。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sub-Saharan Africa has a high burden of pneumococcal diseases. Pneumococcal carriage precedes invasive disease and transmission. The introduction of pneumococcal conjugate vaccines (PCVs) has significantly reduced global vaccine-type (VT) pneumococcal disease, but data on PCVs' long-term impact on VT serotypes in Africa are limited. We aimed to evaluate PCV13's long-term effect on pneumococcal carriage in rural Gambia. METHODS: From January to November 2022, we conducted a population-based, cross-sectional pneumococcal carriage survey in Central and Upper River Regions of The Gambia. We collected data on demographic characteristics, clinical history, risk factors, and PCV status. Nasopharyngeal swabs were taken from randomly selected household members of all ages. Streptococcus pneumoniae was isolated and serotyped using standard methods. We measured the prevalence of pneumococcal carriage by specific age groups, PCV13 vaccination status, and the proportions of different pneumococcal outcomes among carriers. We performed multivariable logistic regression to examine factors associated with VT carriage. RESULTS: Overall, 4087 participants were enrolled; the prevalence of pneumococcal carriage was 32.1% (95% CI: 29.34% - 35.03%). The estimated prevalence of PCV13 VT carriage was 6.4% (95% CI: 5.48% - 7.47%). Children aged 5-9 years had the highest VT carriage prevalence at 13.6% (95% CI: 10.34% - 17.56%). Among fully PCV-vaccinated children under 10, the odds of VT carriage in 5-9-year-olds were 1.60 times higher than in infants aged 0-11 months [AOR = 1.60, 95% CI:1.06-2.41]. The prevalence of VT carriage was similar among fully PCV-vaccinated and unvaccinated children under 10 years of age. Serotypes 19F, 3 and 6A were the most abundant VTs; 19F and 3 were the most prevalent among <5 and 5-14-year-old children, respectively. CONCLUSIONS: Ten years after the introduction of PCV13 in the Gambia, residual VT carriage persists, particularly in age groups in whom direct protection from immunization in infancy has waned. A booster dose or catch-up vaccinations could aid control of VT circulation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Osei I, Mendy E, van Zandvoort K, et al. Effect of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in rural Gambia 10 years after its introduction: A population-based cross-sectional study. Vaccine. 2025. PMID: 40300436. doi:10.1016/j.vaccine.2025.127181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。